We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Epitome to Develop Biomarker Assay Panels for Bristol-Myers Squibb

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epitome to Develop Biomarker Assay Panels for Bristol-Myers Squibb"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Epitome Biosystems has announced that it has signed a technology access and product development agreement with Bristol-Myers Squibb Company for use of Epitome's proprietary EpiTag™ protein measurement platform.

Epitome will develop custom antibody arrays for quantitative and high throughput measurement of proteins specified by Bristol-Myers Squibb to accelerate introduction of newly discovered biomarkers into clinical development programs.

Under the terms of the agreement Epitome will receive development funding and license fees from Bristol-Myers Squibb.

Epitome's EpiTag technology uses an in silico approach to identify peptide tags for any protein based solely on sequence information. Antibodies raised against the tags have predetermined specificity since the tag sequence appears only once in the proteome.

Measurement in the resulting assay system is made on the peptide fragment released from the protein by digestion rather than on the whole protein.

This approach results in a system that is scaleable to any protein in the proteome and allows for efficient development of multiplex protein assays for newly discovered biomarkers.

Neal Gordon, Ph.D., President of Epitome, stated, "The recognition by Bristol-Myers Squibb that our technology addresses a need in moving from biomarker discovery to clinical implementation is extremely gratifying."

"Bristol-Myers Squibb has a strong history of successful drug development and we are very pleased to be working with them."